Most Read This Week
- HRQoL Outcomes in Patients With Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab or Everolimus vs Sunitinib
- VHL Mutation Analysis in Bilateral Clear Cell RCC Distinguishes Between Independent Primary Tumors and Contralateral Metastatic Disease
- Role of PD-L1 Status in mRCC Treated With First-Line Immune-Based Combinations
- Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell RCC
- Sunitinib as a Second-Line Therapy in Patients With Metastatic RCC After Immune Checkpoint Inhibitor–Based Combination Therapy
Recently Updated
- HRQoL Outcomes in Patients With Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab or Everolimus vs Sunitinib
- VHL Mutation Analysis in Bilateral Clear Cell RCC Distinguishes Between Independent Primary Tumors and Contralateral Metastatic Disease
- Role of PD-L1 Status in mRCC Treated With First-Line Immune-Based Combinations
- Comparing iRECIST-Based and Free Text Reporting of CT Scans for Monitoring Metastatic Renal Cell Carcinoma
- Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell RCC